Pluristem Therapeutics (NASDAQ:PSTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “
Several other research firms have also weighed in on PSTI. ValuEngine lowered Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 20th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 16th. Finally, Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.44.
Shares of Pluristem Therapeutics (NASDAQ PSTI) opened at $1.47 on Tuesday. The firm has a market capitalization of $157.44, a price-to-earnings ratio of -4.59 and a beta of 0.21. Pluristem Therapeutics has a twelve month low of $1.06 and a twelve month high of $2.12.
In related news, Director Mark Germain sold 45,873 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $1.48, for a total transaction of $67,892.04. Following the sale, the director now owns 525,584 shares of the company’s stock, valued at $777,864.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.00% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Meitav Dash Investments Ltd. acquired a new stake in shares of Pluristem Therapeutics during the fourth quarter valued at $138,000. Psagot Investment House Ltd. boosted its stake in shares of Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 122,347 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 34,742 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in shares of Pluristem Therapeutics by 363.5% during the fourth quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock valued at $401,000 after acquiring an additional 228,149 shares during the last quarter. 4.20% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Downgrades Pluristem Therapeutics (PSTI) to Hold” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/22/zacks-investment-research-downgrades-pluristem-therapeutics-psti-to-hold.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.